GAITHERSBURG, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that new data showing reductions of multiple classes of atherogenic and cardio-inflammatory lipids in subjects treated with pemvidutide will be presented in a poster session at The Liver Meeting(R) 2024 of the American Association for the Study […]

Patents covering BioVie’s terlipressin liquid formulation now secured in the United States, India, Japan and Chile, and are pending in eight additional markets Liquid formulation has demonstrated room-temperature stability for up to 24 months, representing an important advantage for treating patients with cirrhosis and ascites in the home-care setting CARSON, Nev., Oct. 15, 2024 (GLOBE

WILMINGTON, Del., Oct. 15, 2024 (GLOBE NEWSWIRE) — InterDigital, Inc. (Nasdaq: IDCC), a mobile, video and AI technology research and development company, today announced that the company will release its third quarter 2024 financial results before the market open on Thursday, October 31, 2024. InterDigital executives will host a conference call that same day at

LAS VEGAS, Oct. 15, 2024 (GLOBE NEWSWIRE) — More than 50% of executives expect deepfake attacks to increase over the next 12 months, but only 7% report using new technologies to detect deepfakes*. Meanwhile, researchers are repeatedly demonstrating how AI-generated ID documents, selfie photos, and videos can successfully fool antiquated Know Your Customer (KYC) verification

CAMBRIDGE, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) — Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced it will share new preclinical data at three upcoming scientific meetings. “These preclinical results build upon the foundation of data we have shared

MALVERN, Pa., Oct. 15, 2024 (GLOBE NEWSWIRE) — via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company developing transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), announced today the successful outcome of the End-of-Phase 2 meeting with the U.S. Food

WILMETTE, Ill., Oct. 15, 2024 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients, today announced the filing of a provisional patent covering new therapeutic radiopharmaceuticals based on a family of linkers used to connect radioisotopes with targeting agents, including Monopar’s uPAR targeting antibody

RONKONKOMA, N.Y., Oct. 15, 2024 (GLOBE NEWSWIRE) — Pineapple Energy Inc. (the “Company”) (NASDAQ: PEGY) announced today that effective at 12:01 a.m. Central Time on October 17, 2024, the Company will implement a 1-for-50 reverse stock split of its outstanding common stock, which is within the range approved by stockholders at the annual meeting of

ISELIN, N.J., Oct. 15, 2024 (GLOBE NEWSWIRE) — Provident Bank, a leading New Jersey-based financial institution, has released the results of its First-Time Home Buyer Survey, taking stock of the generational differences in how Americans are navigating a complicated housing market. This year’s survey revealed that, not surprisingly, searching for a first home is extremely

? On track to report topline data from the Phase 2b trial in December 2024 ? Neflamapimod has the potential to restore function and improve cognitive and motor functions in DLB patients ? 96% of patients enrolled in RewinD-LB completed the 16-week portion of the study, of which 98% continued into the open label extension